XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash cash equivalents and federal funds sold | 52.46%36.01M | 105.13%47.24M | 53.21%33.32M | 47.12%32.29M | 47.12%32.29M | 7.13%23.62M | -24.75%23.03M | 7.92%21.75M | 71.80%21.95M | 71.80%21.95M |
-Cash and cash equivalents | 52.57%36.01M | 105.20%47.24M | 56.49%33.3M | 49.52%32.27M | 49.52%32.27M | 8.85%23.61M | -23.87%23.02M | 13.36%21.28M | 88.83%21.59M | 88.83%21.59M |
-Restricted cash and investments | --0 | --0 | -96.57%16K | -95.59%16K | -95.59%16K | -95.58%16K | -97.80%8K | -66.16%467K | -72.99%363K | -72.99%363K |
Receivables | 29.83%32.29M | 26.25%31.46M | 24.05%25.51M | 58.33%30.2M | 58.33%30.2M | 27.20%24.87M | 59.94%24.92M | 26.30%20.56M | 33.00%19.08M | 33.00%19.08M |
Deferred costs | 2.93%9.94M | 10.18%10.61M | 214.10%10.81M | 194.00%10.93M | 194.00%10.93M | 141.62%9.66M | 138.16%9.63M | -20.13%3.44M | -7.95%3.72M | -7.95%3.72M |
Other assets | 48.98%8.87M | 14.09%6.2M | 1.08%5.9M | 4.11%6.44M | 4.11%6.44M | -5.13%5.95M | -7.22%5.44M | -9.15%5.84M | 2.62%6.19M | 2.62%6.19M |
Total assets | 25.15%1.79B | 13.24%1.6B | 15.48%1.54B | 23.78%1.56B | 23.78%1.56B | 18.91%1.43B | 27.29%1.42B | 26.86%1.34B | 29.13%1.26B | 29.13%1.26B |
Liabilities | ||||||||||
Payables | 55.99%1.25M | 72.57%799K | -48.74%449K | 80.13%281K | 80.13%281K | 96.09%802K | 79.46%463K | 457.96%876K | -87.42%156K | -87.42%156K |
-Total tax payable | 55.99%1.25M | 72.57%799K | -48.74%449K | 80.13%281K | 80.13%281K | 96.09%802K | 79.46%463K | 457.96%876K | -87.42%156K | -87.42%156K |
Long term debt and capital lease obligation | 35.75%920.19M | 7.15%785.03M | 9.40%735.44M | 20.89%770.85M | 20.89%770.85M | 10.82%677.84M | 21.44%732.67M | 16.31%672.26M | 20.63%637.64M | 20.63%637.64M |
Other liabilities | 14.24%20.99M | -5.33%14.26M | 7.13%16.3M | 3.70%17.38M | 3.70%17.38M | 26.14%18.38M | -32.86%15.06M | 14.98%15.22M | 13.19%16.76M | 13.19%16.76M |
Total liabilities | 35.30%958.62M | 7.13%813.24M | 9.40%766.7M | 20.05%801.08M | 20.05%801.08M | 10.59%708.52M | 19.09%759.14M | 16.61%700.8M | 20.65%667.28M | 20.65%667.28M |
Shareholders'equity | ||||||||||
Share capital | 16.45%12.51M | 19.36%11.92M | 20.59%11.71M | 17.27%11.26M | 17.27%11.26M | 16.48%10.75M | 28.38%9.99M | 30.63%9.71M | 40.72%9.6M | 40.72%9.6M |
-common stock | 16.45%12.51M | 19.36%11.92M | 20.59%11.71M | 17.27%11.26M | 17.27%11.26M | 16.48%10.75M | 28.38%9.99M | 30.63%9.71M | 40.72%9.6M | 40.72%9.6M |
Paid-in capital | 20.24%903.51M | 23.78%855.18M | 24.90%833.63M | 23.25%796.95M | 23.25%796.95M | 21.87%751.41M | 32.59%690.88M | 35.15%667.44M | 44.25%646.59M | 44.25%646.59M |
Retained earnings | -107.77%-85.58M | -75.99%-75.84M | -66.07%-68.01M | -25.54%-52.53M | -25.54%-52.53M | -1.98%-41.19M | -47.63%-43.09M | -68.09%-40.95M | -308.01%-41.85M | -308.01%-41.85M |
Less: Treasury stock | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | 0.00%23.94M | 0.00%23.94M |
Total stockholders'equity | 15.18%830.44M | 20.29%791.26M | 22.18%777.33M | 27.99%755.68M | 27.99%755.68M | 28.40%720.97M | 38.27%657.77M | 40.45%636.2M | 40.28%590.41M | 40.28%590.41M |
Total equity | 15.18%830.44M | 20.29%791.26M | 22.18%777.33M | 27.99%755.68M | 27.99%755.68M | 28.40%720.97M | 38.27%657.77M | 40.45%636.2M | 40.28%590.41M | 40.28%590.41M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |